respond quickly and effectively to public health threats, using evidence-based programs and interventions.

DATES: The period for this award will be September 30, 2023, through September 29, 2028.

FOR FURTHER INFORMATION CONTACT: Prianca Reddi, Center for Global Health, Centers for Disease Control and Prevention, 1600 Clifton Rd., Atlanta, GA 30329. Telephone: 404–498–2117, Email: *DGHPNOFOs@cdc.gov.*

SUPPLEMENTARY INFORMATION: The single-source award will implement strategies to improve regional and national public health systems and institutions in Africa by strengthening surveillance systems, laboratory networks, information systems, workforce capacity, emergency response and preparedness, public health investigation capacities, and health promotion activities in Africa Centres for Disease Control and Prevention (Africa CDC). This award will also support establishment of strong management practices that will enable Africa CDC to more effectively coordinate and administer its activities. Africa CDC will efficiently manage its responsibilities through transparent and data-driven decision making, robust organizational capacities, and effective internal/external stakeholder communication.

Africa CDC is in a unique position to conduct this work, as it is the only agency that oversees public health for all 55 African countries that are Member States of the African Union and uniquely has the authority to mandate that countries report data about public health events, including cases of disease and outbreaks. Africa CDC's mandate also includes responsibility for the health security of African nations through the establishment and oversight of the public health emergency operations center; national public health laboratory; surveillance; workforce development and through the coordination of public and global health security.

Summary of the Award

Recipient: Africa Centres for Disease Control and Prevention.

Purpose of the Award: The purpose of this award is to strengthen and reinforce Africa's public health systems to prevent, detect, and respond quickly and effectively to public health threats, using evidence-based programs and interventions. The award will implement strategies to improve regional and national public health systems and institutions in Africa by strengthening surveillance systems, laboratory networks, information systems, workforce capacity, emergency response and preparedness, public health investigation capacities, and health promotion activities on the continent and regionally through Africa CDC.

Amount of Award: For Africa CDC the approximate year 1 award is $3,000,000 in Federal Fiscal Year (FFY) 2023 funds, with a total estimated $15,000,000 for the 5-year period of performance, subject to availability of funds. Funding amounts for years 2–5 will be set at continuation.

Authority: This program is authorized under Section 307 of the Public Health Service Act [42 U.S.C. 242*l*] and Section 301(a) [42 U.S.C. 241(a)] of the Public Health Service Act.

Period of Performance: September 30, 2023, through September 29, 2028.

Dated: February 15, 2023.

Terrance Perry,

Chief Grants Management Officer, Centers for Disease Control and Prevention.

[FR Doc. 2023–03530 Filed 2–17–23; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Notice of Award of a Single-Source Cooperative Agreement To Fund the International Federation of Red Cross and Red Crescent Societies (IFRC)

AGENCY: Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

ACTION: Notice.

SUMMARY: The Centers for Disease Control and Prevention (CDC), located within the Department of Health and Human Services (HHS), announces the award of approximately $6,000,000 for Year 1 funding to the International Federation of Red Cross and Red Crescent Societies. The award will utilize IFRC's unique expertise, skills and access to countries and subnational consequential geographies that are inaccessible to CDC personnel, to continue polio eradication activities as well as to deliver measles and other life-saving vaccine preventable disease (VPD) interventions in priority countries. Funding amounts for years 2–5 will be set at continuation.

DATES: The period for this award will be July 1, 2023 through June 30, 2028.

FOR FURTHER INFORMATION CONTACT: Mary A. Mulholland, Center for Global Health, Centers for Disease Control and Prevention, 1600 Clifton Rd. NE, Atlanta, GA 30333, Telephone: 404–553–7371, E-Mail: *mmulholland@cdc.gov.*

SUPPLEMENTARY INFORMATION: The single-source award will support IFRC's polio eradication activities and the delivery of measles and other life-saving vaccine preventable disease (VPD) interventions in priority countries. Through its network of national Red Cross and Red Crescent societies, IFRC has unparalleled community access and provides critical health services and activities in areas which are otherwise inaccessible to CDC due to security restrictions. Extending immunization services to these areas of unreached children is critical to achieving global eradication of polio.

IFRC is in a unique position to conduct this work, as it is one of the three arms of the International Red Cross and Red Crescent Movement, the world's largest humanitarian network whose mission includes protecting life and health in conflict countries and other emergencies. National Red Cross and Red Crescent Societies are a network of community-based volunteers who support the public authorities in their own countries as independent auxiliaries to the government in the humanitarian field. The community-based volunteers provide local knowledge and culturally competent expertise, which provides unparalleled access to communities. IFRC comprises 190-member Red Cross and Red Crescent National Societies globally, a secretariat based in Geneva and more than 60 country offices strategically located to support activities around the world.

Summary of the Award

Recipient: International Federation of Red Cross and Red Crescent Societies.

Purpose of the Award: The purpose of this award is to support efforts to strengthen and sustain global, regional, and national immunization program capacity needed to:

- Achieve the globally agreed goals of the IA2030 (including polio eradication, global and regional elimination targets for select VPDs including measles and rubella, and neonatal tetanus;
- Achieve the 2030 Sustainable Development Goal (SDG) target to end VPDs of children under 5 years of age;
- Reduce chronic disease and cancer deaths from VPDs; and
- Prevent, detect, and respond to VPD outbreaks.

Amount of Award: The approximate year 1 funding amount will be $6,000,000 in Federal Fiscal Year (FYY)

2023 funds, subject to the availability of funds. Funding amounts for years 2–5 will be set at continuation.

Authority: This program is authorized under Section 307 of the PHS Act (42 U.S.C 242); section 317(k)(1) and (2) of the PHS Act (42 U.S.C. 247b(k)(1) and (2).

Period of Performance: 7/1/2023 through 6/30/2028.

Dated: February 15, 2023.

Terrance Perry,

Chief Grants Management Officer, Centers for Disease Control and Prevention.

[FR Doc. 2023–03522 Filed 2–17–23; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2023–N–0343]

Agency Information Collection Activities; Proposed Collection; Comment Request; Current Good Manufacturing Practice for Blood and Blood Components and Reducing the Risk of Transfusion-Transmitted Infections

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA, Agency, or we) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the **Federal Register** concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on information collection associated with current good manufacturing practice (CGMP) for blood and blood components, including information collection recommendations found in Agency guidance related to reducing the risk of transfusion-transmitted infection (TTI).

DATES: Either electronic or written comments on the collection of information must be submitted by April 24, 2023.

ADDRESSES: You may submit comments as follows. Please note that late, untimely filed comments will not be considered. The *https://www.regulations.gov* electronic filing system will accept comments until 11:59 p.m. Eastern Time at the end of April 24, 2023. Comments received by mail/hand delivery/courier (for written/paper submissions) will be considered timely if they are received on or before that date.

Electronic Submissions

Submit electronic comments in the following way:

- *Federal eRulemaking Portal*: *https://www.regulations.gov.* Follow the instructions for submitting comments. Comments submitted electronically, including attachments, to *https://www.regulations.gov* will be posted to the docket unchanged. Because your comment will be made public, you are solely responsible for ensuring that your comment does not include any confidential information that you or a third party may not wish to be posted, such as medical information, your or anyone else's Social Security number, or confidential business information, such as a manufacturing process. Please note that if you include your name, contact information, or other information that identifies you in the body of your comments, that information will be posted on *https://www.regulations.gov.*
- If you want to submit a comment with confidential information that you do not wish to be made available to the public, submit the comment as a written/paper submission and in the manner detailed (see ''Written/Paper Submissions'' and ''Instructions'').

Written/Paper Submissions

Submit written/paper submissions as follows:

- *Mail/Hand Delivery/Courier* (for written/paper submissions): Dockets Management Staff (HFA–305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
- For written/paper comments submitted to the Dockets Management Staff, FDA will post your comment, as well as any attachments, except for information submitted, marked and identified, as confidential, if submitted as detailed in ''Instructions.''

Instructions: All submissions received must include the Docket No. FDA–2023–N–0343 for ''Current Good Manufacturing Practice for Blood and Blood Components and Reducing the Risk of Transfusion-Transmitted Infections.'' Received comments, those filed in a timely manner (see **ADDRESSES**), will be placed in the docket and, except for those submitted as ''Confidential Submissions,'' publicly viewable at *https://www.regulations.gov* or at the Dockets Management Staff between 9 a.m. and 4 p.m., Monday through Friday, 240–402–7500.

- Confidential Submissions—To submit a comment with confidential information that you do not wish to be made publicly available, submit your comments only as a written/paper submission. You should submit two copies total. One copy will include the information you claim to be confidential with a heading or cover note that states ''THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will review this copy, including the claimed confidential information, in its consideration of comments. The second copy, which will have the claimed confidential information redacted/blacked out, will be available for public viewing and posted on *https://www.regulations.gov.* Submit both copies to the Dockets Management Staff. If you do not wish your name and contact information to be made publicly available, you can provide this information on the cover sheet and not in the body of your comments and you must identify this information as ''confidential.'' Any information marked as ''confidential'' will not be disclosed except in accordance with 21 CFR 10.20 and other applicable disclosure law. For more information about FDA's posting of comments to public dockets, see 80 FR 56469, September 18, 2015, or access the information at: *https://www.govinfo.gov/content/pkg/FR-2015-09-18/pdf/2015-23389.pdf.*

Docket: For access to the docket to read background documents or the electronic and written/paper comments received, go to *https://www.regulations.gov* and insert the docket number, found in brackets in the heading of this document, into the ''Search'' box and follow the prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852, 240–402–7500.

FOR FURTHER INFORMATION CONTACT: Domini Bean, Office of Operations, Food and Drug Administration, Three White Flint North, 10A–12M, 11601 Landsdown St., North Bethesda, MD 20852, 301–796–5733, *PRAStaff@fda.hhs.gov.*

SUPPLEMENTARY INFORMATION: Under the PRA (44 U.S.C. 3501–3521), Federal Agencies must obtain approval from the Office of Management and Budget (OMB) for each collection of information they conduct or sponsor. ''Collection of information'' is defined in 44 U.S.C. 3502(3) and 5 CFR 1320.3(c) and includes Agency requests or requirements that members of the public submit reports, keep records, or provide information to a third party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A)) requires Federal